Canopy Growth (CGC) Cash & Current Investments (2017 - 2026)
Canopy Growth (CGC) posted Cash & Current Investments of $265.9 million for Q1 2026, little changed sequentially from $266.3 million in Q4 2025, and up 190.25% YoY from $91.6 million in Q1 2025.
Canopy Growth (CGC) Cash & Current Investments (2017 - 2026) Analysis & Trends
Canopy Growth has reported Cash & Current Investments for 10 years, with the latest figure at $265.9 million in Q1 2026.
- Quarterly Cash & Current Investments rose 190.25% year-over-year to $265.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265.9 million (up 190.25% YoY) and the FY2026 annual result came in at $265.9 million, up 190.25% from the prior year.
- Cash & Current Investments steadied at $265.9 million in Q1 2026 per CGC's latest filing, from $266.3 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $1.1 billion in Q1 2022 and troughed at $91.6 million in Q1 2025.
- A 5-year average of $354.6 million and a median of $187.2 million in 2023 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2023 and 2026: Cash & Current Investments slumped 78.65% in 2023, then soared 190.25% in 2026.
- Over 5 years, Cash & Current Investments stood at $581.4 million in 2022, then tumbled by 76.48% to $136.8 million in 2023, then declined by 6.65% to $127.7 million in 2024, then jumped by 108.57% to $266.3 million in 2025, then retreated by 0.13% to $265.9 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $265.9 million, $266.3 million, and $94.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 164.00 Mn |
| 10 | Canopy Growth | 434.93 Mn | 187.92 Mn | 16.08 Mn | 247.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 247.01 Mn |
| Mar 31, 2026 | 265.93 Mn |
| Dec 31, 2025 | 266.27 Mn |
| Sep 30, 2025 | 94.07 Mn |
| Jun 30, 2025 | 95.29 Mn |
| Mar 31, 2025 | 91.62 Mn |
| Dec 31, 2024 | 127.67 Mn |
| Sep 30, 2024 | 172.93 Mn |
| Jun 30, 2024 | 146.12 Mn |
| Mar 31, 2024 | 131.81 Mn |
| Dec 31, 2023 | 136.76 Mn |
| Sep 30, 2023 | 187.20 Mn |
| Jun 30, 2023 | 403.79 Mn |
| Mar 31, 2023 | 413.25 Mn |
| Dec 31, 2022 | 581.44 Mn |
| Sep 30, 2022 | 876.71 Mn |
| Jun 30, 2022 | 954.63 Mn |
| Mar 31, 2022 | 1.08 Bn |
| Dec 31, 2021 | 1.13 Bn |
| Sep 30, 2021 | 651.29 Mn |